An increasing number of studies in both preclinical and clinical models have evaluated the effects of BTR agonists on ghrelin, CCK, GLP-1, and PYY secretion, although the specificity of bitter compounds for different T2Rs is poorly defined and the function of intestinal BTR sensing in either obesity or type 2 diabetes has not been thoroughly investigated. The gene discussed is CCK; the disease is obesity due to melanocortin 4 receptor deficiency.